UK markets open in 5 hours 47 minutes
  • NIKKEI 225

    23,642.70
    +75.66 (+0.32%)
     
  • HANG SENG

    24,569.54
    +27.28 (+0.11%)
     
  • CRUDE OIL

    41.41
    -0.29 (-0.70%)
     
  • GOLD FUTURES

    1,919.00
    +3.60 (+0.19%)
     
  • DOW

    28,308.79
    +113.37 (+0.40%)
     
  • BTC-GBP

    9,250.01
    +715.67 (+8.39%)
     
  • CMC Crypto 200

    240.99
    +2.08 (+0.87%)
     
  • ^IXIC

    11,516.49
    +37.61 (+0.33%)
     
  • ^FTAS

    3,315.73
    +3.96 (+0.12%)
     

Global Zika Virus Market Spotlight Report 2020: All Clinical Trials have Been in Either Phase I or Phase II, with No Phase III Trials to Date

Research and Markets
·3-min read

Dublin, Oct. 05, 2020 (GLOBE NEWSWIRE) -- The "Market Spotlight: Zika Virus" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Zika virus market, comprising key pipeline therapies, clinical trials, probability of success, epidemiology, and licensing and acquisition deals.

Key Takeaways

  • The Zika virus was first reported in continental South America in Brazil in May 2015. In February 2016, between 440,000 and 1,300,000 people were infected in Brazil. In the US, about 225 Zika virus cases were reported in August 2017. In addition, 554 cases were reported in people infected through local mosquito-borne transmission. Furthermore, autochthonous Zika virus transmission was reported in 25 countries in the Americas, Africa, and Asia.

  • In 2016, it was estimated that there were between 508 and 1,778 imported cases in Europe, particularly in France, Portugal, and Italy.

  • The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with just a single product in Phase II.

  • Therapies in development for Zika virus focus on the immune system, viral antigens, and RNA polymerase. Candidates comprise DNA vaccines such as the National Institutes of Health's Zika Virus Vaccine, GeneOne's GLS-5700, and Inovio's INO-A002; Moderna's mRNA vaccine; Themis Bioscience's recombinant viral vector vaccine; Imutex's AGS-v vaccine; hVIVO's AGS-v PLUS vaccine; Johnson & Johnson's Ad26.ZIKV.001 vaccine; Takeda's TAK-426 vaccine; Emergent BioSolutions' ZIKV-IG; Valneva's VLA 1601; and BioCryst's galidesivir, a broad-spectrum antiviral drug.

  • The overall likelihood of approval of a Phase I antiviral asset is 14.3%, and the average probability a drug advances from Phase III is 71.3%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.

  • All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.

  • The US leads in terms of the number of Zika virus clinical trials globally.

  • Inovio, GeneOne, and Emergent BioSolutions have two completed trials each in the Zika virus space.

  • Inovio leads industry sponsors with four clinical trials for Zika virus, followed by GeneOne, Moderna, and Sanofi.

Key Topics Covered:

Overview

Key Takeaways

Disease Background

Treatment

  • Vaccines

  • Therapeutics

Epidemiology

Pipeline Drugs

Key Regulatory Events

  • FDA Revokes Emergency Authorization On Ebola, Zika Tests

Probability of Success

Clinical Trial Landscape

  • Sponsors by status

  • Sponsors by phase

Bibliography

Appendix

Companies Mentioned

  • National Institutes of Health

  • GeneOne

  • Inovio

  • Moderna

  • Themis Bioscience

  • Imutex

  • hVIVO

  • Johnson & Johnson

  • Takeda

  • Emergent BioSolutions

  • Valneva

  • BioCryst

  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/8hpfmn

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900